Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Fortune III who wrote (487)	4/16/1998 12:34:00 PM
From: Aishwarya	Read Replies (1) \| Respond to of 2887

BILL AND ALL, Since a good number of you have held this stock over a very long period of time you all would be easily be able to see the trendline as a positive on this little gem that needs polishing. Sine the last two years on a gradual decline all the longs always knew that the 100% Silicone line of products was a no brainer and clearly a winner strategy. But the train got derailed and work has been done to bring it on track. Of course the only department that failed miserably was sales, on the other hand they made great strides in terms of evolving their products and getting FDA approvals through clinical trials. After the company hired Marshall Kerr he has been dissecting the company and i cannot find evidence of any thing going wrong. They are not just doing things right but they are also doing the right things. That is extremely important and crucial to the success of our little company. Here is a clip from the previous news release: Marshall Kerr, American BioMed's Vice President, Sales and Marketing, added, ''The company expects to see increased international sales activity for the OmniCath(R) later this year as a result of the clinical trials conducted by our Japanese partners. The clinical data collected for the Japanese registration process for the OmniCath(R), combined with the company's continuing U.S. clinical trials, will enhance and support our international sales efforts.'' They are going to be all over the place Europe, japan , Turkey and a huge distribution network will be in place. With a little bit of luck we could be at $4 level someday if all goes well as planned. Besides the post i put out earlier shows why this company is severely undervalued if you compare the price which AVEI paid for their recent acquisition of World medical Manufacturing. Go ABMI Sri.